Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.69 Bil Enterprise Value: 14.74 Bil PE Ratio: 72.28 PB Ratio: 2.89 GF Score: 71/100

Biomarin Pharmaceutical Inc at Jefferies London Healthcare Conference Transcript

Nov 16, 2022 / 09:35AM GMT
Release Date Price: $86.22 (+2.35%)
Akash Tewari
Jefferies LLC, Research Division - Equity Analyst

For those who don't know me, my name is Akash Tewari. I'm one of the therapeutic analysts here at Jefferies, and I have the pleasure of hosting BioMarin. And joining us today, we have Brian Mueller, CFO; and Jeff Ajer, Chief Commercial Officer, 2 of the people I would love to talk to, especially as BioMarin is transitioning from not only just a rare disease company, but what we're hoping for is a real EPS and revenue acceleration story, something that I think really changes the financial profile of the company and really expands the amount of shareholders who are going to be interested in your stock over the next few years.

Maybe before I get in with my own specific questions, I'll hand it off to Brian for some opening remarks, and we'll take it from there.

Brian R. Mueller
BioMarin Pharmaceutical Inc. - Executive VP of Finance & CFO

Thank you, Akash. I appreciate it. Really appreciate the opportunity to be with you in London here today.

Here we are just a few weeks from

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot